Printer Friendly

Karo Bio patents estrogen receptor complex.

Karo Bio (Huddinge, Sweden; 46-8-608 6018) an-nounced that the company has received patent protec-tion for three-dimensional structures of the estrogen receptor beta. Estrogen acts by binding to its receptor in cells of target tissues. The receptor is a protein with hundreds of amino acids and contains thousands of atoms with a specific three-dimensional arrangement. Female sex hormones and pharmaceutical compounds function by affecting the three-dimensional arrangement structure of the receptor. Knowledge about the three-dimensional arrangement structure is therefore of great importance for design of new pharmaceutical compounds.

Karo Bio has now received United States patent protection for several three-dimensional arrangement structures in complex with different chemical compounds. This is significant since there are two separate receptors for estrogen, the female sex hormone. The two receptors perform different functions and development of receptor selective compounds may lead to new treatments in the field of women's health care.

Karo Bio has previously received patent protection for use of the gene encoding ER beta and has filed several patents covering new clinical indications, chemical compounds and receptor structure related information. The new issued patent is therefore an important piece in a broad and long-term patent strategy.

Karo Bio employs 120 people and has 250 patent cases including 100 approved

patents.

Karo Bio has been listed on the Stockholm stock exchange (KARO) since 1998 and has a leading position in the field of drug discovery and nuclear receptors. Nuclear receptors are important and validated drug targets for a number of clinical indications and the company uses proprietary technologies for the development of novel and improved therapies for major markets. An important base for generation of new therapeutic strategies is Karo Bio's strong academic network.

Karo Bio has drug discovery programs in therapeutic areas such as women's health care, metabolic disorders, cardiovascular disease, diabetes, dermatology, ophthal-mology and infectious disease.

Karo Bio collaborates with major pharmaceutical comp-anies for development of products through clinical trials and marketing. In these partnerships Karo Bio receives downpayments, R&D funding and royalties on net sales when products reach the market.

Karo Bio's product pipeline is strong and includes a number of proprietary projects that will be partnered in different stages. Karo Bio generally collaborates with major pharmaceutical companies from early drug dis-covery through clinical trials but also takes the oppor-tunity to bring products to the clinic before partnering. Apart from financial compensations the partners bring competence and resources for drug development and marketing to the collaboration.

Karo Bio has one product in clinical trials and expects to enter clinical trials with partners in the future.

Karo Bio has a strong financial position and its partner-ships include Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Aventis Pharma, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc. GPC Biotech, Nov-Immune S.A., and Serono International S.A.
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Karo Bio patents estrogen receptor complex.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 1, 2001
Words:460
Previous Article:Immunomedics obtains patent for therapy of B-cell malignancies using antibodies.
Next Article:Genta licenses antisense technology to Epigenesis.
Topics:


Related Articles
Clogged arteries block hormone effects.
Gpc Biotech and Karo Bio announce drug discovery alliance for novel genomics-derived antibacterial targets.
Good Estrogen, Bad Estrogen.
Novogen awarded United States patent for isoflavones to treat estrogen-dependent disorders.
Wake Forest obtains United States patent.
New patent suits address groundbreaking techniques.
Mechanisms of endocrine resistance.
Century Technology obtains United States patent.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters